Login to Your Account



Orexigen settles Takeda dispute, seeks expanded reach for obesity drug in South Korea

By Michael Fitzhugh
Staff Writer

Thursday, August 6, 2015
Orexigen Therapeutics Inc. reported higher-than-expected second quarter revenues, helped by royalties on U.S. sales of obesity drug Contrave (naltrexone and bupropion).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription